WebsiteGear Logo Log In
New User? Sign Up
About | Contact | FAQ
  Home News Website Related Online Marketing Sunday, June 25, 2017 
Add Press Release News | News Feeds Feeds | Email This News Email

Hemophilia Disease Forecast and Market, 2035 - Research and Markets
Friday, May 19, 2017

DUBLIN, May 19, 2017 /PRNewswire/ --

Research and Markets has announced the addition of the "Hemophilia Disease Forecast and Market Analysis to 2035" report to their offering.

Hemophilia is a relatively rare hereditary genetic disorder characterized by an inability to produce a clot capable of stopping bleeding. Mainly men are affected by hemophilia A (factor VIII-deficient) and hemophilia B (factor IX-deficient), as is the case with most recessive, X-chromosomal disorders. In congenital hemophilia, the impaired production or functioning of one of the factors involved in the coagulation cascade is responsible for compromised blood coagulation, leading to uncontrolled and prolonged bleeding. The current standard of treatment for these patients is the replacement of the missing factor via clotting factor concentrate products. However, some patients develop antibodies against these therapies, called inhibitors, making treatment much more difficult.

Patients without hemophilia who develop inhibitors against clotting factor VIII or factor IX are diagnosed as having acquired hemophilia A or B, respectively. Although acquired hemophilia patients and congenital hemophilia patients with inhibitors share some similar traits and treatment options, acquired hemophilia affects men and women similarly, and has a distinct bleeding pattern.

Another disease associated with blood coagulation dysfunction is von Willebrand disease, which is caused by a deficiency in von Willebrand factor. Although von Willebrand disease is more common than hemophilia, it is relatively less severe, with most patients exhibiting mild disease that does not require regular treatment unless bleeding episodes caused by trauma or invasive procedures are uncontrollable.

Key Topics Covered:


    --  Advate
    --  Adynovate
    --  Alprolix
    --  BAX 817
    --  BAY 94-9027
    --  BeneFIX
    --  CSL627
    --  Eloctate
    --  FEIBA
    --  Idelvion
    --  Ixinity
    --  Kogenate/Helixate and Kovaltry
    --  N8-GP
    --  N9-GP
    --  NovoEight
    --  NovoSeven
    --  Nuwiq
    --  Rixubis
    --  Vonvendi
    --  Xyntha/ReFacto


    --  Disease Definition and Diagnosis
    --  Patient Segmentation
    --  Current Treatment Options
    --  Prescribing Trends


    --  Disease Background
    --  Sources and Methodology
    --  Forecast: Hemophilia
    --  Forecast: Von Willebrand Disease
    --  Epidemiologist Insight
    --  Strengths and Limitations


    --  Product profile: Advate
    --  Product profile: Adynovate
    --  Product profile: Alprolix
    --  Product profile: BeneFIX
    --  Product profile: Eloctate
    --  Product profile: FEIBA
    --  Product profile: Idelvion
    --  Product profile: Ixinity
    --  Product profile: Kogenate FS
    --  Product profile: NovoEight
    --  Product profile: NovoSeven
    --  Product profile: Rixubis
    --  Product profile: Xyntha


    --  Product profile (late stage): BAX 817
    --  Product profile (late stage): BAY 94-9027
    --  Product profile (late stage): CSL627
    --  Product profile (late stage): CSL689
    --  Product profile (late stage): Kovaltry
    --  Product profile (late stage): LR769
    --  Product profile (late stage): N8-GP
    --  Product profile (late stage): N9-GP
    --  Product profile (late stage): emicizumab


For more information about this report visit

Media Contact:

Laura Wood, Senior Manager

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

To view the original version on PR Newswire, visit:

SOURCE Research and Markets

Email This News Email | Submit To Slashdot Slashdot | Submit To Digg | Submit To | News Feeds Feeds

Nav Eastern Michigan University Goes Live with Ex Libris Alma and Summon Integration | Jun 25, 2017
Nav BBDO Worldwide Is Named Network Of The Year At The Cannes Lions International Festival Of Creativity For Record-Setting 6th Time | Jun 24, 2017
Nav Omnicom Agencies Win Top Honors at the 2017 Cannes Lions Festival of Creativity | Jun 24, 2017
Nav Director of National intelligence and Central Intelligence Agency Director to Speak at 2017 Aspen Security Forum | Jun 23, 2017
Nav Infor Announces Details for Q4 Fiscal Year 2017 Investor Call | Jun 23, 2017
Nav TuneGO┬« Inc. to Present at the Reach China Investment Conference 2017 in Beijing | Jun 23, 2017
Nav Internet Marketing Company, fishbat, Discusses Tips for Starting Your First Professional Blog | Jun 23, 2017
Nav Technical Reports on Internet Equities -- Yahoo, GrubHub, Yandex, and Akamai Technologies | Jun 23, 2017
Nav Daily Technical Summary Reports on Services Stocks -- Thomson Reuters, Time, Gannett, and New York Times | Jun 23, 2017
Nav ProfNet Experts Available on PTSD Awareness, Fidget Spinners, More | Jun 23, 2017

Submit News | View More News View More News